Netherlands· NL-3e68ed24b777
Selincro 18 mg, filmomhulde tablet
A nalmefene product containing nalmefeenhydrochloride 2-water, registered in Netherlands by H. Lundbeck A/S. The same ATC class is registered in 14 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Nalmefene is registered in 14 of 19 countries.
Countries holding a registration under ATC N07BB05 (nalmefene), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Nalmefene · ATC N07BB05
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of nalmefene costs, country by country.
Normalised to the WHO defined daily dose (18 mg), the median price runs from $3.31 in France to $6.33 in Switzerland — a ×1.9 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Nalmefene · price per daily dose (18 mg)
USD · FX 28 Sept 2026
- CH Switzerland$6.33
- FR France$3.31
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- NALMEFEENHYDROCHLORIDE 2-WATER
- Manufacturer
- H. Lundbeck A/S
- Country
- Netherlands (NL)
- ATC code
- N07BB05
- ATC class
- Nalmefene
- Defined daily dose
- 18 mg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/12/815
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
5 interactions on record for nalmefene.
Graded by severity as the source publishes them — 4 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nalmefene · interactions on record
5 records
- 4 moderate
- 1 minor
Most severe, free to view
- Methylnaltrexone bromideA06AH01moderate
- NaloxegolA06AH03moderate
- NaldemedineA06AH05moderate
- GlimepirideA10BB12moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nalmefene in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSELINCROH. Lundbeck A/S, Valby
- SpainSELINCRO 18 MG COMPRIMIDOS RECUBIERTOS CON PELICULAH. Lundbeck A/S
- SwitzerlandSelincro, FilmtablettenLundbeck (Schweiz) AG
- IrelandSelincro 18 mg film-coated tabletsH. Lundbeck A/S
- IcelandSelincroH. Lundbeck A/S*
- NorwaySelincroH.Lundbeck
- PolandSelincroH. Lundbeck A/S
- BelgiumSelincro 18 mgH. Lundbeck
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- Germany · Nalfino
- France · Nalmefene Biogaran
- Iceland · Selincro
- Norway · Selincro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/91b3a97c-40ce-440e-b82c-d263685fd153 GET /v1/drugs/91b3a97c-40ce-440e-b82c-d263685fd153?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/selincro-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Nalmefene",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp111338",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"CROSPOVIDON (E 1202)",
"HYPROMELLOSE (E 464)",
"LACTOSE 0-WATER",
"MACROGOL 400",
"MAGNESIUMSTEARAAT (E 470b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"NALMEFEENHYDROCHLORIDE 2-WATER"
],
"leaflet_url": null,
"authorised_at": "2013/02/25",
"procedure_number": "EMEA/H/C/002583",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/12/815",
"additional_monitoring": "Y"
}See everything about nalmefene.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.